JP2016529246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529246A5 JP2016529246A5 JP2016532263A JP2016532263A JP2016529246A5 JP 2016529246 A5 JP2016529246 A5 JP 2016529246A5 JP 2016532263 A JP2016532263 A JP 2016532263A JP 2016532263 A JP2016532263 A JP 2016532263A JP 2016529246 A5 JP2016529246 A5 JP 2016529246A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- gene
- therapeutic agent
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 20
- 229940124597 therapeutic agent Drugs 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 12
- -1 Methyl (S)-{4- (3′-cyanobiphenyl-4-yl) -2,3,9-trimethyl-6H-thieno [3,2-f] [1,2,4] tri-azolo [ 4,3-a] [1,4] diazepin-6-yl} acetate Chemical compound 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000007962 solid dispersion Substances 0.000 claims 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 101150053046 MYD88 gene Proteins 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- FGNAJWFZOBYZLR-UHFFFAOYSA-N 3h-[1,2,4]triazolo[4,3-a][1,4]diazepine Chemical compound N1=CC=CN2CN=NC2=C1 FGNAJWFZOBYZLR-UHFFFAOYSA-N 0.000 claims 2
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 2
- 206010069754 Acquired gene mutation Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 claims 2
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 claims 2
- 101150104237 Birc3 gene Proteins 0.000 claims 2
- 101150001392 CD79B gene Proteins 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 101100219559 Homo sapiens CARD11 gene Proteins 0.000 claims 2
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 2
- 101150101999 IL6 gene Proteins 0.000 claims 2
- 101150046106 IRAK1 gene Proteins 0.000 claims 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 2
- 101150099493 STAT3 gene Proteins 0.000 claims 2
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 claims 2
- 101150095338 TLR6 gene Proteins 0.000 claims 2
- 101150090104 TNFRSF17 gene Proteins 0.000 claims 2
- 101150080074 TP53 gene Proteins 0.000 claims 2
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 claims 2
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 claims 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 150000004683 dihydrates Chemical class 0.000 claims 2
- 230000009477 glass transition Effects 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 108700025694 p53 Genes Proteins 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000037439 somatic mutation Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361862772P | 2013-08-06 | 2013-08-06 | |
| US201361862752P | 2013-08-06 | 2013-08-06 | |
| US61/862,772 | 2013-08-06 | ||
| US61/862,752 | 2013-08-06 | ||
| US201361909703P | 2013-11-27 | 2013-11-27 | |
| US61/909,703 | 2013-11-27 | ||
| PCT/EP2014/002164 WO2015018521A1 (en) | 2013-08-06 | 2014-08-06 | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016529246A JP2016529246A (ja) | 2016-09-23 |
| JP2016529246A5 true JP2016529246A5 (cg-RX-API-DMAC7.html) | 2017-09-21 |
Family
ID=51298706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532263A Ceased JP2016529246A (ja) | 2013-08-06 | 2014-08-06 | Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160158246A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3030242A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016529246A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160037201A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105899212A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015018521A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX384074B (es) | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| EP3110424A1 (en) | 2014-02-28 | 2017-01-04 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| KR20170037670A (ko) * | 2014-08-19 | 2017-04-04 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법 |
| MX376748B (es) | 2014-10-27 | 2025-03-07 | Tensha Therapeutics Inc | Inhibidores del bromodominio. |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
| MX2018003824A (es) * | 2015-10-02 | 2019-04-01 | Dana Farber Cancer Inst Inc | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control. |
| CN114569606B (zh) | 2016-07-29 | 2024-04-19 | 英克特诺治疗公司 | 吲哚啉酮化合物的用途 |
| JP7129973B2 (ja) * | 2016-10-20 | 2022-09-02 | セルジーン クオンティセル リサーチ，インク． | ブロモドメイン阻害剤 |
| UA127413C2 (uk) * | 2017-07-04 | 2023-08-16 | Джянгсу Хенгруй Медісін Ко., Лтд. | Фармацевтична композиція та спосіб її отримання |
| CN107879989B (zh) * | 2017-11-29 | 2020-01-03 | 重庆市中药研究院 | 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法 |
| CN107759607B (zh) * | 2017-11-29 | 2019-08-23 | 上海万巷制药有限公司 | 具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法 |
| JP2021517119A (ja) * | 2018-03-05 | 2021-07-15 | クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン | 腫瘍溶解性アデノウイルスとｃｄｋ４／６阻害剤との組み合わせによる腫瘍の処置 |
| EP4074842A4 (en) * | 2019-12-11 | 2023-09-06 | Tsinghua University | LONG NON-CODING RNA LETN AS A TUMOR MARKER AND THERAPEUTIC TARGET |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2412776C (en) * | 2000-06-16 | 2011-03-15 | Mitsubishi Pharma Corporation | Compositions controlling release ph range and/or speed |
| US8476260B2 (en) * | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| MX384074B (es) * | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) * | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| JP6265979B2 (ja) * | 2012-06-25 | 2018-01-24 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 |
| HK1211209A1 (en) * | 2012-09-28 | 2016-05-20 | Oncoethix Gmbh | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
-
2014
- 2014-08-06 WO PCT/EP2014/002164 patent/WO2015018521A1/en not_active Ceased
- 2014-08-06 US US14/910,344 patent/US20160158246A1/en not_active Abandoned
- 2014-08-06 CN CN201480055171.2A patent/CN105899212A/zh active Pending
- 2014-08-06 EP EP14748126.1A patent/EP3030242A1/en not_active Withdrawn
- 2014-08-06 KR KR1020167004844A patent/KR20160037201A/ko not_active Withdrawn
- 2014-08-06 JP JP2016532263A patent/JP2016529246A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529246A5 (cg-RX-API-DMAC7.html) | ||
| JP2015531747A5 (cg-RX-API-DMAC7.html) | ||
| JP5976778B2 (ja) | キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体 | |
| ES2586588T3 (es) | Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa | |
| RU2591191C2 (ru) | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы | |
| JP2017517579A5 (cg-RX-API-DMAC7.html) | ||
| JP2016525563A5 (cg-RX-API-DMAC7.html) | ||
| JP2017514907A5 (cg-RX-API-DMAC7.html) | ||
| AU2012327210B2 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| JP2017529332A5 (cg-RX-API-DMAC7.html) | ||
| CN104039798A (zh) | 具有蛋白激酶抑制活性的噻吩并[3,2-d]嘧啶衍生物 | |
| JP2013539789A5 (cg-RX-API-DMAC7.html) | ||
| JP2012136540A5 (cg-RX-API-DMAC7.html) | ||
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| RU2015133528A (ru) | Замещенные полициклические пиразольные ингибиторы киназной активности и их применение | |
| JP2015528447A5 (cg-RX-API-DMAC7.html) | ||
| JP2015504091A5 (cg-RX-API-DMAC7.html) | ||
| JP2017504635A5 (cg-RX-API-DMAC7.html) | ||
| JP2014518544A5 (cg-RX-API-DMAC7.html) | ||
| PT1644376E (pt) | Derivados de pirrolo [3,4-c] pirazole activos como inibidores da cinase | |
| JP2012513416A5 (cg-RX-API-DMAC7.html) | ||
| JP2013540712A5 (cg-RX-API-DMAC7.html) | ||
| JP2019512535A5 (cg-RX-API-DMAC7.html) | ||
| RU2017100921A (ru) | Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина | |
| JP2021501208A5 (cg-RX-API-DMAC7.html) |